FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
0.0007.01.110.07.02

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Plant County Management  The Address of Reporting Person*					2. Issuer Name <b>and</b> Ticker or Trading Symbol Inozyme Pharma, Inc. [ INZY ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Bhagat Sarah M				-					•			X Direct	or		L0% Ow	ner	
(Last)	`	rst) (	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/23/2020								Officer (give title below)			Other (specify below)	
321 SUMMER STREET, SUITE 400				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street) BOSTON	N M	Α (	02210									X Form filed by One Reporting Person Form filed by More than One Reporting Person				- 1	
(City)	(Si	tate) (	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Transaction te onth/Day/Ye	Execution Date			Code (Instr.   5)				Benefic	es ially Following	6. Owners Form: Dir (D) or Ind (I) (Instr.	ect c rect E	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	Amount	(A) o (D)	r Price	Transac (Instr. 3	tion(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code (				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow For Dire or I (I) (	nership n: ect (D) ndirect nstr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$16	07/23/2020		A		9,367		(1)	07/22/2030	Common Stock	9,367	\$0.00	9,367		D		

### **Explanation of Responses:**

1. The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

#### Remarks:

/s/ Stephen Basso, as attorneyin-fact for Sarah Bhagat

07/24/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.